Janelle House, DO
Family Medicine · Cameron, TXNPI 1356480594
Payments from drug & device makers
Across 339 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- UCB, Inc.$427
- Astellas Pharma US Inc$370
- Ironshore Pharmaceuticals Inc.$340
- Bayer$234
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,79797%
- Education$1803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $1,288 |
| AbbVie(2 entities) | 76 | $1,234 |
| UCB, Inc. | 15 | $427 |
| Astellas Pharma US Inc | 15 | $370 |
| Ironshore Pharmaceuticals Inc. | 17 | $340 |
| Bayer | 8 | $234 |
| Lilly USA, LLC | 13 | $197 |
| Eisai Inc. | 13 | $159 |
| Novartis | 9 | $149 |
| Sumitomo Pharma America, Inc. | 9 | $141 |
| Merck | 7 | $136 |
| Sunovion Pharmaceuticals Inc. | 12 | $133 |
| Xeris Pharmaceuticals, Inc. | 8 | $128 |
| Amgen(2 entities) | 6 | $108 |
| Pfizer | 6 | $85 |
| Corium, LLC | 3 | $74 |
| Urovant Sciences Inc | 4 | $72 |
| Mylan Specialty L.p. | 4 | $71 |
| Genentech USA, Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Exact Sciences | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Biogen | 3 | $47 |
| AstraZeneca | 3 | $44 |
| Abbott | 2 | $40 |
| Lundbeck LLC | 2 | $31 |
| Johnson & Johnson | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| GSK | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| CMP Pharma, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$105
How this compares
$5,977 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 944 | $298,957 |
| JardianceEmpagliflozin | 330 | $130,936 |
| XareltoRivaroxaban | 248 | $74,661 |
| OzempicSemaglutide | 67 | $73,450 |
| MyrbetriqMirabegron | 177 | $66,523 |
| GemtesaVibegron | 240 | $61,413 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $41,572 |
| VraylarCariprazine Hcl | 23 | $31,278 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $26,975 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 97 | $24,952 |
| EntrestoSacubitril/Valsartan | 79 | $23,020 |
| Potassium Chloride | 674 | $20,413 |
| TivicayDolutegravir Sodium | 17 | $20,111 |
| AptiomEslicarbazepine Acetate | 22 | $19,055 |
| Gabapentin | 885 | $17,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $298,957944 claims |
| Johnson & JohnsonXarelto | $28 | $74,661248 claims |
| Novo NordiskOzempic | $1,288 | $73,45067 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $22 | $67,079120 claims |
| Astellas Pharma US IncMyrbetriq | $370 | $66,523177 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $141 | $61,413240 claims |
| AbbVieVraylar, Linzess | $1,234 | $41,16535 claims |
| MerckJanuvia, Janumet, Belsomra | $136 | $33,34767 claims |
| NovartisEntresto | $149 | $23,02079 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $133 | $19,05522 claims |
| AstraZenecaBreztri Aerosphere | $44 | $16,62324 claims |
| BayerKerendia | $234 | $14,59629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Cameron
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.